Q4 2025 earnings call highlights: 2026 guidance to $100B sales, EPS outlook, key drug growth and risks—read the insights now.

By Michael Erman and Mrinalika Roy Jan 21 (Reuters) - Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...

Medtech giant Johnson & Johnson JNJ announced better-than-expected fourth-quarter 2025 results on Jan. 21, 2026. The company ...

And by the end of the decade, J&J is expecting double-digit annual growth, said CEO Joaquin Duato on an analysts' call.

JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related ...

Johnson & Johnson’s JNJ fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of ...

JNJ stock price today: Johnson & Johnson stock saw a dip even as the company projected robust 2026 sales and profit figures.

Johnson & Johnson reports Q4 earnings Jan 21 with 22% EPS growth expected. Stelara biosimilars and talc verdict weigh on ...

Johnson & Johnson beat Q4 earnings and sales estimates, driven by strong cancer and MedTech growth, and issued a higher 2026 ...